Illinois General Assembly - Bill Status for HB5581
Illinois General Assembly

Previous General Assemblies

 Bill Status of HB5581  97th General Assembly


House Sponsors
Rep. Ann Williams - Edward J. Acevedo

Last Action
DateChamber Action
  1/8/2013HouseSession Sine Die

Statutes Amended In Order of Appearance
225 ILCS 85/25.3 new
225 ILCS 85/30from Ch. 111, par. 4150

Synopsis As Introduced
Amends the Pharmacy Practice Act. Provides that a biosimilar product determined to be interchangeable by the United States Food and Drug Administration shall be available for substitution in the State in accordance with the Act and the Illinois Food, Drug and Cosmetic Act, provided that each manufacturer submits to the Director of the Department of Public Health a notification containing product interchangeability information as a prerequisite to product substitution when they have FDA product approval, as interchangeable, and, in any event, the information shall be submitted no later than 60 days prior to product substitution in the State. Sets forth provisions concerning prescription forms. Provides that a pharmacy may substitute a prescription biosimilar product for a prescribed product only under certain circumstances. Sets forth provisions concerning publication and compliance. Provides that a violation of the biosimilar products provision shall be include in the list of causes for which the Department of Financial and Professional Regulation may take disciplinary or non-disciplinary action as the Department may deem proper. Effective January 1, 2013.

DateChamber Action
  2/15/2012HouseFiled with the Clerk by Rep. Ann Williams
  2/15/2012HouseAdded Chief Co-Sponsor Rep. Edward J. Acevedo
  2/15/2012HouseFirst Reading
  2/15/2012HouseReferred to Rules Committee
  1/8/2013HouseSession Sine Die

Back To Top